DOMINO-HD состоит из двух фаз; в первой фазе изучаются методы достоверного измерения факторов образа жизни (физическая активность, сон, диета) у людей с болезнью Гентингтона (БГ) с наименьшим вмешательством нормальную жизнь. Во второй фазе будет использована информация, собранная в фазе 1, для измерения этих факторов образа жизни у людей с БГ в течение 12 месяцев. Основная цель DOMINO-HD — изучить, как сон, питание и физическая активность влияют на прогрессирование болезни Гентингтона, чтобы разработать новые способы поддержки и управления основными аспектами жизни пациентов с БГ. В ходе исследования также будет изучено, как цифровые технологии, такие как фитнес-браслеты, могут быть использованы для поддержки людей с БГ.
Предполагаемая дата завершения исследования: сентябрь 2022 года
18 лет и старше
Все
Носители гена БГ
Взрослые (старше 18 лет) с диагнозом болезни Гентингтона, подтвержденным генетическим тестированием, которые могут ходить без посторонней помощи и участвуют (в настоящее время или в последнее время) в исследовании Enroll-HD.
Общие вопросы
Cheney Drew
Tel: +44 (0)29 2068 7243
drewc5@cardiff.ac.uk
Набор участников для этого финансируемого ЕС обсервационного исследования, которое позволит получить новые данные о том, связаны ли факторы поведения и образа жизни с генетическим риском и прогрессированием БГ, наконец-то начался в феврале 2022г. после задержек, вызванных пандемией.
TRIAL SITE:
Universitätsklinikum Ulm
Address: Ulm, Baden-Württemberg, Germany, 89081
CONTACT
Nana Kovacevic
nana.kovacevic@uniklinik-ulm.de
TRIAL SITE:
University College Dublin, Ireland
Address: University College Dublin, Belfield, Dublin 4, Irland
CONTACT
Madeleine Lowery
Tel: +353 1 716 1911
madeleine.lowery@ucd.ie
TRIAL SITE:
Institute of Psychiatry and Neurology, Warsaw
Address: Jana III Sobieskiego 9, Warszawa, 02-957
CONTACT
Malgorzata Dusza-Rowinska
Tel: +48 694 904 208
m.dusza.rowinska@gmail.com
TRIAL SITE:
Hospital Universitario de Burgos
Address: Neurology Department, Avda Islas Baleares 3, Burgos, 09006
CONTACT
Carla Collazo
Tel: 947 256 533 ext 35380
ccollazo@ubu.es
TRIAL SITE:
University Hospital Zurich
Address: Zürich, Switzerland, 08091
CONTACT
Hans Jung
hans.jung@usz.ch
Klavs Renerts
klavs.renerts@usz.ch
TRIAL SITE (Lead site):
Cardiff University
Address: Cardiff, United Kingdom, CF24 4HQ
CONTACT
Philippa Jones
Tel: +44 29206 87269
dominohd@cardiff.ac.uk
a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.
You do not know if you carry the genetic mutation for HD gene
A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity.
means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.
A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.
a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.
A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD
The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD
the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein
How well a person can handle a treatment without having serious or uncomfortable side effects.
Part of the brain that coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.
A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.
a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity
Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.
Prior to onset or diagnosis of movement symptoms.
A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.
The movement of drugs through the body
The body’s biological response to drugs
Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.
Brain cells that store and transmit information
Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones
Mutant huntingtin protein. The protein produced by the faulty HD gene.
after HD diagnosis, or when symptoms are already showing
A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once
one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15
functional MRI:As with MRI, a technique using powerful magnetic fields but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes
A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.
A measure of whether a treatment works or not
A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene
a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable
Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.
one of the two copies of a gene
Liquid component of the blood.
The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.
Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.
